NEW YORK, March 3, 2021 /PRNewswire/ — atai Life Sciences (“atai” or the “Company”), a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced the successful closing of its $157 million Series D financing round. The round was led by our existing investors Apeiron Investment Group, the family office of atai’…


Previous articleRed Light Holland’s iMicro Digital Care App Launches Virtual Telecounseling with a Membership Program Led by Certified Therapist and Microdosing Expert
Next articleMINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury